Professor Shen Jingshan completed his Master's degree in Medicinal Chemistry at China Pharmaceutical University in 1995 and received a Ph.D. in Organic Chemistry at Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 1998. Shen is currently a principal investigator and doctoral supervisor at SIMM.

Among the drug discovery projects in his group, VV116 was conditionally approved and VV934 was approved in China as anti-SARS-CoV-2 drugs; VV116 and TPN171 were launched in Uzbekistan for treating COVID-19 and erectile dysfunction (ED) respectively; six other drug candidates are at different stages of clinical research in China. 

Shen has also gained rich experience in industrial-oriented research and manufacturing of active pharmaceutical ingredients. And his group proposed a practical strategy in organic process research and development named “Control from Root Design”. This prioritizes the design and evaluation of the route of synthesis from the very beginning of a project under the principles of Green & Sustainable Chemistry to achieve safer, easier, environment friendly, and cost-efficient processes for industrial application.

Education 

1995.09 - 1998.07 Ph.D. degree in Organic Chemistry, the Shanghai Institute of Materia Medica, Chinese Academy of Sciences

1992.09 - 1995.07 Master degree in Medicinal Chemistry, China Pharmaceutical University

Work Experience 

2006-Present  Professor and Principal Investigator, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

2001-2005  Associated Professor, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

1998-2000  Assistant Professor, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

1. New drug discovery and development for the treatments of diseases related to the central nervous system and infection. 

2. Green and sustainable chemistry with a strategy of "control from root design": an industry-oriented innovative campaign aimed to design and evaluate the route of synthesis from the very beginning of a project under the principles of Green & Sustainable Chemistry to achieve a safer, easier, environment friendly, and cost-efficient process for industrial application.

1. 2021.11-2024.12  National key research and development plan, clinical study of oral nucleoside anti-SARS-CoV-2 candidate drug VV116.

2. 2021.01-2022.07  Shanghai Science and Technology Major project, the development of key technologies for sugar drug research and the development of original varieties——key technologies for the preparation of ribonucleoside compounds.

3. 2020.02-2021.01  Shanghai Science and Technology Commission, Research and development of anti-SARS-CoV-2 emergency drugs.

4. 2019.11-2022.10  Science and Technology Commission of Shanghai Municipality，Integrated drug resistance based on phenotypic screening, artificial intelligence, characteristic natural products and efficient synthesis.

5. 2019.01-2020.09  National Science and Technology Major Project，Registration of the hepatitis C drug sofibuvir in Central Asia.